Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunoglobulin therapy for refractory Crohn's disease.

Literature DB >> 24587823

Immunoglobulin therapy for refractory Crohn's disease.

Shailja Shah¹, Jonathan Terdiman², Katherine Gundling³, Uma Mahadevan⁴.

Abstract

Entities: Disease

Keywords: Crohn’s disease; immunoglobulin; inflammatory bowel disease

Year: 2014 PMID： 24587823 PMCID： PMC3903086 DOI： 10.1177/1756283X13504728

Source DB: PubMed Journal: Therap Adv Gastroenterol ISSN： 1756-283X Impact factor: 4.409

× No keyword cloud information.

14 in total

1. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis.

Authors: D S Levine; S H Fischer; D L Christie; R C Haggitt; H D Ochs
Journal: Am J Gastroenterol Date: 1992-01 Impact factor: 10.864

2. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.

Authors: Hubertus Köller; Michael Schroeter; Heinrich Feischen; Hans-Peter Hartung; Bernd C Kieseier
Journal: J Neurol Date: 2006-08-11 Impact factor: 4.849

3. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors: H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal: J Clin Immunol Date: 2000-03 Impact factor: 8.317

Review 4. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors: Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal: J Clin Immunol Date: 2012-06-23 Impact factor: 8.317

5. Treatment of Crohn's disease and ulcerative colitis with 7S-immunoglobulin.

Authors: G Rohr; K Kusterer; M Schille; R Gladisch; U Schwedes; J Teuber; K H Usadel
Journal: Lancet Date: 1987-01-17 Impact factor: 79.321

Review 6. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route.

Authors: Ann Gardulf
Journal: BioDrugs Date: 2007 Impact factor: 5.807

Review 7. Pyoderma gangrenosum treated with high-dose intravenous immunoglobulins: Two cases and review of the literature.

Authors: Nicolas Meyer; Valérie Ferraro; Marie-Henriette Mignard; Henri Adamski; Jacqueline Chevrant-Breton
Journal: Clin Drug Investig Date: 2006 Impact factor: 2.859

8. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

Authors: William J Sandborn; Brian G Feagan; Richard N Fedorak; Ellen Scherl; Mark R Fleisher; Seymour Katz; Jewel Johanns; Marion Blank; Paul Rutgeerts
Journal: Gastroenterology Date: 2008-07-17 Impact factor: 22.682

Immunoglobulin therapy for refractory Crohn's disease.

1. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis.

2. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.

3. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Review 4. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

5. Treatment of Crohn's disease and ulcerative colitis with 7S-immunoglobulin.

Review 6. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route.

Review 7. Pyoderma gangrenosum treated with high-dose intravenous immunoglobulins: Two cases and review of the literature.

8. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

9. [Treatment of Crohn disease with intravenous immunoglobulin].

10. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.

1. Gastrointestinal Manifestations in X-linked Agammaglobulinemia.

Review 2. IgG and Fcγ Receptors in Intestinal Immunity and Inflammation.

3. Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report.

Review 4. Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets.